Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation

Tohoku Journal of Experimental Medicine

Volumn 220, Issue 2, 2010, Pages 121-126

  Ando, Toshihiko ^a   Mitani, Noriyuki ^a   Matsunaga, Kimie ^a   Nakazora, Tatsuki ^a   Gondo, Toshikazu ^a   Yujiri, Toshiaki ^a   Tanizawa, Yukio ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute myelogenous leukemia; Allogeneic hematopoietic stem cell transplantation; Extramedullary relapse; Gemtuzumab ozogamicin; Graft versus leukemia effect

Indexed keywords

CD33 ANTIGEN; FLUORODEOXYGLUCOSE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE BIOPSY; BONE LESION; BONE MARROW; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; LEUKEMIA CELL; LIVER INJURY; LOW BACK PAIN; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SIDE EFFECT; SOFT TISSUE DISEASE; THROMBOCYTOPENIA;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE AND BONES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; LUMBOSACRAL REGION; MALE; MIDDLE AGED; PEROXIDASE; RECURRENCE; SARCOMA, MYELOID; TRANSPLANTATION, HOMOLOGOUS;

EID: 77949482707     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.220.121     Document Type: Article

References (19)

1. Békássy, A.N., Hermans, J., Gorin, N.C. & Gratwohl, A. (1996) Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant., 17, 801-808.
2. Berthou, C., Leglise, M.C., Herry, A., Balcon, D., Hardy, E., Lessard, M. & Abgrall, J-F. (1998) Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia, 12, 1676-1681.
3. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. & Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res., 7, 1490-1496.
4. Chong, G., Byrnes, G., Szer, J. & Grigg, A. (2000) Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant., 26, 1011-1015.
5. Dinndorf, P.A., Andrews, R.G., Benjamin, D., Ridgway, D., Wolff, L. & Bernstein, I.D. (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood, 67, 1048-1053.
6. Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D.A. & Bernstein, I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem., 13, 47-58.
7. Jiang, Y.Z., Cullis, J.O., Kanfer, E.J., Goldman, J.M. & Barrett, A.J. (1993) T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant., 11, 133-138.
8. Jilani, I., Estey, E., Huh, Y., Joe, Y., Manshouri, T., Yared, M., Giles, F., Kantarjian, H., Cortes, J., Thomas, D., Keating, M., Freireich, E. & Albitar, M. (2002) Differences in CD33 intensity between various myeloid neoplasms. Am. J. Clin. Pathol., 118, 560-566.
9. Larson, R.A., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E.A., Sievers, E.L., Mineur, P., Bennett, J.M., Berger, M.S., Eten, C.B., Munteanu, M., Loken, M.R., Va n Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R; Mylotarg Study Group. (2002) Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 16, 1627-1636.
10. Larson, R.A., Sievers, E.L., Stadtmauer, E.A., Löwenberg, B., Estey, E.H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J.M., Richie, M., Leopold, L.H., Berger, M.S., Sherman, M.L., Loken, M.R., van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in frst recurrence. Cancer, 104, 1442-1452.
11. Mortimer, J., Blinder, M.A., Schulman, S., Appelbaum, F.R., Buckner, C.D., Clift, R.A., Sanders, J.E., Storb, R. & Thomas, E.D. (1989) Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J. Clin. Oncol., 7, 50-57.
12. Owonikoko, T., Agha, M., Balassanian, R., Smith, R. & Raptis, A. (2007) Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. Nat. Clin. Pract. Oncol., 4, 491-495.
13. Piccaluga, P.P., Martinelli, G., Rondoni, M., Malagola, M., Gaitani, S., Isidori, A., Bonini, A., Gugliotta, L., Luppi, M., Morselli, M., Sparaventi, G., Visani, G. & Baccarani, M. (2004) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk. Lymphoma, 45, 1791-1795.
14. Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. & Bernstein, I.D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, 3678-3684.
15. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R; Mylotarg Study Group. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol., 19, 3244-3254.
16. Simpson, D.R., Nevill, T.J., Shepherd, J.D., Fung, H.C., Horsman, D.E., Nantel, S.H., Vickars, L.M., Sutherland, H.J., Toze, C.L., Hogge, D.E., Klingemann, H.G., Naiman, S.C. & Barnett, M.J. (1998) High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant., 22, 259-264.
17. Sullivan, K.M., Weiden, P.L., Storb, R., Witherspoon, R.P., Fefer, A., Fisher, L., Buckner, C.D., Anasetti, C., Appelbaum, F.R., Badger, C., Beatty, P., Bensinger, W., Berenson, R., Bigelow, C., Cheever, M.A., Clift, R., Deeg, H.J., Doney, K., Greenberg, P., Hansen, J.A., Hill, R., Loughran, T., Martin, P., Neiman, P., Petersen, F.B., Sanders, J., Singer, J., Stewart, P. & Thomas, E.D. (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood, 73, 1720-1728.
18. Wadleigh, M., Richardson, P.G., Zahrieh, D., Lee, S.J., Cutler, C., Ho, V., Alyea, E.P., Antin, J.H., Stone, R.M., Soiffer, R.J. & DeAngelo, D.J. (2003) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102, 1578-1582.
19. Zein, N., Poncin, M., Nilakantan, R. & Ellestad, G.A. (1989) Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. Science, 244, 697-699.